J4T Stock Overview
A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Onconetix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.89 |
| 52 Week Low | US$0.089 |
| Beta | 3.73 |
| 11 Month Change | -2.94% |
| 3 Month Change | -8.08% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| J4T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | 5.1% | 0.4% |
| 1Y | n/a | -14.3% | 3.9% |
Return vs Industry: Insufficient data to determine how J4T performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how J4T performed against the German Market.
Price Volatility
| J4T volatility | |
|---|---|
| J4T Average Weekly Movement | 29.8% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: J4T's share price has been volatile over the past 3 months.
Volatility Over Time: J4T's weekly volatility has increased from 21% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Ralph Schiess | onconetix.gcs-web.com |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. Fundamentals Summary
| J4T fundamental statistics | |
|---|---|
| Market cap | €2.95m |
| Earnings (TTM) | -€42.77m |
| Revenue (TTM) | €710.56k |
4.6x
P/S Ratio-0.1x
P/E RatioIs J4T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J4T income statement (TTM) | |
|---|---|
| Revenue | US$758.90k |
| Cost of Revenue | US$1.70m |
| Gross Profit | -US$938.16k |
| Other Expenses | US$44.74m |
| Earnings | -US$45.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | -123.62% |
| Net Profit Margin | -6,019.47% |
| Debt/Equity Ratio | -105.5% |
How did J4T perform over the long term?
See historical performance and comparison